Acute toxicity to vitamin A can occur when adults or children ingest >100x or >20x the RDA, respectively, over a period of hours or a few days.A37787 The RDA for vitamin A differs depending on age and sex and can range from 300 - 900 ?g retinol activity equivalents (RAE) per day.L15386 Symptoms of acute systemic toxicity generally include mucocutaneous involvement (e.g. xerosis, cheilitis, skin peeling) and may involve mental status changes.A216971 Children are typically more susceptible to acute vitamin A toxicity - daily intakes of as little as 1500 IU/kg have been observed to result in toxicity.A37787
Chronic vitamin A toxicity can develop following the long-term ingestion of high vitamin A doses. While there is a wide variation in the lowest toxic vitamin A dose, the ingestion of >25 000 IU daily for 6 years or 100,000 IU daily for 6 months is considered to be toxic.A37787 Chronic vitamin A toxicity can affect many organ systems and can lead to the development of osteoporosis and CNS effects (e.g. headaches).A216971
Retinol and derivatives of retinol that play an essential role in metabolic functioning of the retina, the growth of and differentiation of epithelial tissue, the growth of bone, reproduction, and the immune response. Dietary vitamin A is derived from a variety of carotenoids found in plants. It is enriched in the liver, egg yolks, and the fat component of dairy products.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Orlistat | Orlistat can cause a decrease in the absorption of Vitamin A resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Bexarotene | The risk or severity of adverse effects can be increased when Vitamin A is combined with Bexarotene. |
| Diethylstilbestrol | The therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Vitamin A. |
| Estradiol | The therapeutic efficacy of Estradiol can be decreased when used in combination with Vitamin A. |
| Ethinylestradiol | The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Vitamin A. |
| Mestranol | The therapeutic efficacy of Mestranol can be decreased when used in combination with Vitamin A. |
| Estradiol cypionate | The therapeutic efficacy of Estradiol cypionate can be decreased when used in combination with Vitamin A. |
| Estradiol valerate | The therapeutic efficacy of Estradiol valerate can be decreased when used in combination with Vitamin A. |
| Estetrol | The therapeutic efficacy of Estetrol can be decreased when used in combination with Vitamin A. |
| Desogestrel | The therapeutic efficacy of Desogestrel can be decreased when used in combination with Vitamin A. |
| Megestrol acetate | The therapeutic efficacy of Megestrol acetate can be decreased when used in combination with Vitamin A. |
| Levonorgestrel | The therapeutic efficacy of Levonorgestrel can be decreased when used in combination with Vitamin A. |
| Medroxyprogesterone acetate | The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Vitamin A. |
| Norethisterone | The therapeutic efficacy of Norethisterone can be decreased when used in combination with Vitamin A. |
| Ethynodiol diacetate | The therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Vitamin A. |
| Norgestimate | The therapeutic efficacy of Norgestimate can be decreased when used in combination with Vitamin A. |
| Drospirenone | The therapeutic efficacy of Drospirenone can be decreased when used in combination with Vitamin A. |
| Cyproterone acetate | The therapeutic efficacy of Cyproterone acetate can be decreased when used in combination with Vitamin A. |
| Gestodene | The therapeutic efficacy of Gestodene can be decreased when used in combination with Vitamin A. |
| Hydroxyprogesterone caproate | The therapeutic efficacy of Hydroxyprogesterone caproate can be decreased when used in combination with Vitamin A. |
| Dienogest | The therapeutic efficacy of Dienogest can be decreased when used in combination with Vitamin A. |
| Norethynodrel | The therapeutic efficacy of Norethynodrel can be decreased when used in combination with Vitamin A. |
| Norgestrel | The therapeutic efficacy of Norgestrel can be decreased when used in combination with Vitamin A. |
| Gestrinone | The therapeutic efficacy of Gestrinone can be decreased when used in combination with Vitamin A. |
| Lynestrenol | The therapeutic efficacy of Lynestrenol can be decreased when used in combination with Vitamin A. |
| Chlormadinone | The therapeutic efficacy of Chlormadinone can be decreased when used in combination with Vitamin A. |
| Norgestrienone | The therapeutic efficacy of Norgestrienone can be decreased when used in combination with Vitamin A. |
| Quingestanol | The therapeutic efficacy of Quingestanol can be decreased when used in combination with Vitamin A. |
| Demegestone | The therapeutic efficacy of Demegestone can be decreased when used in combination with Vitamin A. |
| Nomegestrol acetate | The therapeutic efficacy of Nomegestrol acetate can be decreased when used in combination with Vitamin A. |
| Acitretin | The risk or severity of adverse effects can be increased when Vitamin A is combined with Acitretin. |
| Alitretinoin | The risk or severity of adverse effects can be increased when Vitamin A is combined with Alitretinoin. |
| Tretinoin | The risk or severity of adverse effects can be increased when Vitamin A is combined with Tretinoin. |
| Tazarotene | The risk or severity of adverse effects can be increased when Vitamin A is combined with Tazarotene. |
| Etretinate | The risk or severity of adverse effects can be increased when Vitamin A is combined with Etretinate. |
| Isotretinoin | The risk or severity of adverse effects can be increased when Vitamin A is combined with Isotretinoin. |
| 4-Oxoretinol | The risk or severity of adverse effects can be increased when Vitamin A is combined with 4-Oxoretinol. |
| Fenretinide | The risk or severity of adverse effects can be increased when Vitamin A is combined with Fenretinide. |
| Ro 12-7310 | The risk or severity of adverse effects can be increased when Vitamin A is combined with Ro 12-7310. |
| Zuretinol acetate | The risk or severity of adverse effects can be increased when Vitamin A is combined with Zuretinol acetate. |
| Motretinide | The risk or severity of adverse effects can be increased when Vitamin A is combined with Motretinide. |
| Valproic acid | Valproic acid may increase the Pseudotumor Cerebri activities of Vitamin A. |
| Doxycycline | The risk or severity of pseudotumor cerebri can be increased when Vitamin A is combined with Doxycycline. |
| Clomocycline | The risk or severity of pseudotumor cerebri can be increased when Vitamin A is combined with Clomocycline. |
| Tigecycline | The risk or severity of pseudotumor cerebri can be increased when Vitamin A is combined with Tigecycline. |
| Oxytetracycline | The risk or severity of pseudotumor cerebri can be increased when Vitamin A is combined with Oxytetracycline. |
| Demeclocycline | The risk or severity of pseudotumor cerebri can be increased when Vitamin A is combined with Demeclocycline. |
| Tetracycline | The risk or severity of pseudotumor cerebri can be increased when Vitamin A is combined with Tetracycline. |
| Metacycline | The risk or severity of pseudotumor cerebri can be increased when Vitamin A is combined with Metacycline. |
| Minocycline | The risk or severity of pseudotumor cerebri can be increased when Vitamin A is combined with Minocycline. |
| Rolitetracycline | The risk or severity of pseudotumor cerebri can be increased when Vitamin A is combined with Rolitetracycline. |
| Sarecycline | The risk or severity of pseudotumor cerebri can be increased when Vitamin A is combined with Sarecycline. |
| Eravacycline | The risk or severity of pseudotumor cerebri can be increased when Vitamin A is combined with Eravacycline. |
| Omadacycline | The risk or severity of pseudotumor cerebri can be increased when Vitamin A is combined with Omadacycline. |
| Penimepicycline | The risk or severity of pseudotumor cerebri can be increased when Vitamin A is combined with Penimepicycline. |
| Methotrexate | The risk or severity of adverse effects can be increased when Methotrexate is combined with Vitamin A. |
| Lymecycline | The risk or severity of pseudotumor cerebri can be increased when Lymecycline is combined with Vitamin A. |
| Oxymetazoline | The absorption of Vitamin A can be decreased when combined with Oxymetazoline. |
| Palovarotene | The risk or severity of adverse effects can be increased when Vitamin A is combined with Palovarotene. |